3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Primary Myelofibrosis
2
Myeloproliferative Disorders
2
Myelodysplastic Syndromes
2
Thrombocythemia, Essential
1
Recurrence
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Leukemia
1
Glioblastoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
ruxolitinib
7
givinostat hydrochloride
3
givinostat
3
anagrelide
3
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
3
bomedemstat
2
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
2
LY2784544
2
spartalizumab
1
sonidegib
1
sabatolimab
1
navitoclax
1
lestaurtinib
1
imetelstat
1
ON 01910
1
NIS-793
1
N-((5-bromo-2-thienyl)sulfonyl)-2,4-dichlorobenzamide
1
INCB057643
1
Fentanyl
1
Diagnosis
1
Decitabine
1
Celecoxib
1
CPI-0610
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Thrombocythemia, Essential
×
INCB057643
×
Clear all
NCT04279847
2026-04-01
LIMBER
Incyte Corporation
Phase 1
Active not recruiting
140 enrolled